ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2018年04月23日 10時00分
Source:
Eisai
エーザイ、非オピオイド系重度慢性疼痛治療薬「Prialt(R)」に関する権利をRiemser社に譲渡
東京, 2018年04月23日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、非オピオイド系重度慢性疼痛治療薬「Prialt(R)」(一般名:ziconotide acetate、以下 「Prialt」)の欧州における独占的開発権および販売権を Riemser Pharma GmbH (本社:ドイツ ベルリン、CEO: Konstantin von Alvensleben、以下 Riemser 社)に対して譲渡する契約を締結しましたのでお知らせします。
本契約に基づき、当社は Riemser 社に対し、「Prialt」の欧州における独占的開発権および販売権を譲渡するとともに、契約一時金を受領します。
当社は、2006 年 2 月に、Elan Corporation PLC(当時)と締結した契約に基づき、本剤の欧州における開発・製造・販売の独占的権利を獲得し、非オピオイド系の髄腔内投与による重度慢性疼痛治療剤として、欧州で販売してきました。
Riemser 社は、欧州全域に拠点を持ち、がん、神経、感染症などのニッチ領域における医療用医薬品の販売、流通に強みを有するスペシャリティー・ファーマです。欧州市場に強い基盤を持つ Riemser社への権利譲渡は、欧州の重度慢性疼痛の患者様へのさらなる貢献を可能とするものです。
当社グループは、神経領域とがん領域を重点領域と位置づけており、これら領域の画新的新薬の開発の加速と地域特性に合致した最適なビジネスモデルの追求により、世界中の患者様とそのご家族の多様なニーズの充足とベネフィット向上により一層貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2018/news201835.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi High-Tech and University of Tokyo Promote Joint Research for the Practical Application of High-resolution Laser-PEEM in the Semiconductor Field
Nov 07, 2024 18:19 JST
Mitsubishi Motors Acquires Its Own Shares from Nissan
Nov 07, 2024 17:20 JST
Honda Signs Sponsorship Agreement to Provide Electrified Vehicles at World Athletics Championships Tokyo 25
Nov 07, 2024 17:10 JST
Home of Fujitsu joint conservation project designated as first Nationally Certified Sustainably Managed Natural Site in Okinawa
Nov 07, 2024 14:51 JST
NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting
Nov 07, 2024 11:40 JST
Anime Tokyo Station 1st Anniversary Event: Celebrating one year since the opening of the new hub for sharing Japanese anime
Nov 07, 2024 11:00 JST
57% of Banking Executives Struggle with Data Silos, Blocking AI-Driven Personalization, CleverTap's New Report Highlights
Nov 06, 2024 15:30 JST
Honda Unveils Electric Motorcycle Concept Models "EV Fun Concept" and "EV Urban Concept" at EICMA 2024
Nov 06, 2024 14:15 JST
Yoshimoto Kogyo and Mitsubishi Corporation have signed a business partnership agreement for co-creation of business using "laughter"
Nov 06, 2024 11:51 JST
Honda to Begin European Verification Test of Battery Sharing Service with GoCimo
Nov 06, 2024 10:39 JST
Honda Unveils World's First and New V3 Engine with Electrical- Compressor at EICMA 2024
Nov 06, 2024 09:03 JST
Victory and world title for TOYOTA GAZOO Racing
Nov 05, 2024 17:59 JST
Tokyo Stock Exchange and Fujitsu announce renewal of cash equity trading system 'arrowhead4.0'
Nov 05, 2024 17:13 JST
Mitsubishi Heavy Industries Continues Order Intake, Revenue, and Profit Growth in Strong First Half, Raises Full-Year Order Intake Guidance
Nov 05, 2024 14:37 JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 05, 2024 11:35 JST
Asahi Kasei and Honda Sign Shareholders' Agreement to Convert Existing Asahi Kasei Subsidiary into Joint Venture for Production of Lithium-ion Battery Separators in Canada
Nov 04, 2024 14:12 JST
Joby Aviation and Toyota Accelerate Efforts to Realize Air Mobility
Nov 04, 2024 09:36 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Nov 01, 2024 13:56 JST
All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024
Nov 01, 2024 12:43 JST
Fujitsu's groundbreaking computing technology for accelerating scientific computing wins Japan Patent Office Commissioner's Award
Nov 01, 2024 12:24 JST
More Latest Release >>
Related Release
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
11/5/2024 11:35:00 AM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
11/1/2024 1:56:00 PM JST
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
10/31/2024 1:56:00 PM JST
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
10/31/2024 11:33:00 AM JST
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
10/17/2024 8:01:00 PM JST
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
10/17/2024 3:59:00 PM JST
Amyotrophic Lateral Sclerosis Treatment "Rozebalamin(R) for Injection 25 mg" Receives The Good Design Award 2024 for Light- Proof Vial Packaging
10/16/2024 7:14:00 PM JST
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
10/8/2024 2:00:00 PM JST
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
10/2/2024 11:28:00 AM JST
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis
9/24/2024 4:06:00 PM JST
More Press release >>